Key reimbursement updates | Philips to acquire SpectraWAVE | New CCTA software from Siemens Healthineers

For years, imaging experts have predicted that CCTA may become the primary imaging modality for coronary artery disease and eliminate the need for invasive diagnostic catheterizations. That prediction is now coming true.

A growing number of private insurers are now covering these advanced technologies. Roosha Parikh, MD, told Cardiovascular Business that the hard work of SCCT and other groups has helped make this happen. 

Massachusetts-based SpectraWAVE has gained considerable momentum in recent years, planting its flag in some of cardiology’s biggest trends. The company was co-founded by cardiologists and has already secured multiple FDA clearances.

According to Heartflow, its AI offering saves health systems nearly $1,400 per patient thanks to reductions in unnecessary cardiovascular testing.

The new software, announced at RSNA 2025 in Chicago, was built to evaluate CCTA images for signs of coronary artery disease and improve cath lab efficiency. 

It is still unclear which imaging exams President Donald Trump underwent to evaluate his cardiovascular health. The White House shared a memo Monday as an attempt to put this topic to bed—but questions remain. 

Calcium in the coronary arteries is a known cardiac risk factor. However, new data suggest it may actually tell us more about a person's overall health than researchers previously believed.